TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (INFINITY)
In: ChalabM, FanchLF, Dkstra KK, Van den Berg JG, Aalbers AG, Sorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, Maas M, Mertz M, Venga V, Bounova G, Broeks A, Beets-Tan RG, de Wkerslooth TR, van Lent AU, Marsman HA, Nuten E, Kok NF, Kuer M, Verbeek WH, Kok M, Van Leerdam ME, Schumacher TN, Voest EE, Haanen JB. Neoadjuvant munotherapy leads to pathologal responses MMR-profnt and MMR-defnt early-stage colon cancers. Nat Med. 2020 Apr;26(4):566-576. do 10.1038/s41591-020-0805-8. Epub 2020 Apr 6. TremelImumab aNd Durvalumab Combination For the Non-operatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-arm, Multi-cohort, Phase II INFINITY Study.
Online
report
Titel: |
TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (INFINITY)
|
---|---|
Link: | |
Quelle: | ChalabM, FanchLF, Dkstra KK, Van den Berg JG, Aalbers AG, Sorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, Maas M, Mertz M, Venga V, Bounova G, Broeks A, Beets-Tan RG, de Wkerslooth TR, van Lent AU, Marsman HA, Nuten E, Kok NF, Kuer M, Verbeek WH, Kok M, Van Leerdam ME, Schumacher TN, Voest EE, Haanen JB. Neoadjuvant munotherapy leads to pathologal responses MMR-profnt and MMR-defnt early-stage colon cancers. Nat Med. 2020 Apr;26(4):566-576. do 10.1038/s41591-020-0805-8. Epub 2020 Apr 6. TremelImumab aNd Durvalumab Combination For the Non-operatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-arm, Multi-cohort, Phase II INFINITY Study. |
Medientyp: | report |
Sonstiges: |
|